Table 1.

Drugs with anticancer efficacy via targeting mitochondrial bioenergetics

Target	Drug	Cancer types	Developmental phase	References
Mitochondrial biogenesis
Mitochondrial HSP90	Gamitrinib	Melanoma, glioblastoma	Preclinical	(Zhang et al. 2016; Ghosh et al. 2015)
Mitochondrial ribosome	Several antibiotics	Multiple types	Repositioning	(Lamb et al. 2015; De Luca et al. 2015)
Oxidative phosphorylation
Mitochondrial complex I	Biguanides	Multiple types	Repositioning	(Birsoy et al. 2014; Hirsch et al. 2009)
	Rotenone	Glioblastoma	Repositioning	(Janiszewska et al. 2012)
	BAY 87-2243	Melanoma	Preclinical	(Schöckel et al. 2015)
	IACS-010759	AML and solid tumors	Phase 1 clinical	(Molina et al. 2018)
Mitochondrial complexes	Graphene	Multiple types	Preclinical	(Zhou et al. 2014)
MCT1/2	AR-C155858	Breast cancer	Preclinical	(Lamb et al. 2014)
Unknown	Nitazoxanide	Colorectal cancer	Repositioning	(Senkowski et al. 2015)
	Niclosamide	Breast cancer, Ovarian cancer	Repositioning	(Wang et al. 2013; Yo et al. 2012)
Fatty acid oxidation
CPT1	Etomoxir	Multiple types	Repositioning	(Camarda et al. 2016; Lin et al. 2017; Tan et al. 2018)
	Perhexiline	Multiple types	Repositioning	(Rodriguez-Enriquez et al. 2015)
	ST1326	Lymphoma, leukemia	Preclinical	(Samudio and Konopleva 2015)
Unknown	Avocatin B	AML	Preclinical	(Lee et al. 2015b)
PPARα	NXT629	Melanoma, Ovarian cancer	Preclinical	(Stebbins et al. 2017)